Healthcare / Medical DevicesTokyo
$1973.00
-42.00 (-2.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $946.0M · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.2B
P/E
12.7x
↓EV/EBITDA
3.3x
↓ROE
7.0%
↑Gross Margin
49.8%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.7%
FCF CAGR
-21.9%
FCF margin
9.5%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.91B · net income $1.00B · FCF $946.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.91B | $9.91B | $10.28B | $9.37B | $9.70B |
| Net Income | $1.00B | $1.00B | $1.35B | $1.15B | $1.28B |
| EBITDA | $1.40B | $1.40B | $1.95B | $1.76B | $1.98B |
| EPS | 145.08 | 145.08 | 172.95 | 136.35 | 150.85 |
| Gross Margin | 49.8% | 49.8% | 50.1% | 49.4% | 49.7% |
| Operating Margin | 13.1% | 13.1% | 17.9% | 17.6% | 19.2% |
| Net Margin | 10.1% | 10.1% | 13.1% | 12.3% | 13.2% |
| Balance Sheet | |||||
| Current Ratio | 5.09 | 5.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $946.0M | $946.0M | $1.04B | $748.5M | $1.98B |
| Returns | |||||
| ROE | 7.0% | 7.0% | 9.8% | 7.0% | 8.2% |
| Valuation | |||||
| P/E | 12.71 | 12.71 | 10.10 | 13.36 | 10.21 |
| EV/EBITDA | 3.29 | 3.29 | 2.57 | 2.06 | 0.79 |
| P/B | 0.95 | 0.95 | 0.98 | 0.94 | 0.84 |
| Growth & Yield | |||||
| Revenue Growth | -3.7% | -3.7% | 9.8% | -3.4% | — |
| EPS Growth | -16.1% | -16.1% | 26.8% | -9.6% | — |
| Dividend Yield | 4.7% | 4.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.5%
EPS terminal req.
$175.07
Spread vs growth
-22.6%
5Y implied EPS CAGR
7.9%
EPS terminal req.
$211.84
Spread vs growth
-24.0%
10Y implied EPS CAGR
8.9%
EPS terminal req.
$341.16
Spread vs growth
-25.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+15.2%
Start / end P/E
10.3x → 13.6x
EPS bridge
172.95 → 145.08
Residual
-5.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.